Literature DB >> 21653664

Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

Marit J van Gils1, Diana Edo-Matas, Emma J Bowles, Judith A Burger, Guillaume B Stewart-Jones, Hanneke Schuitemaker.   

Abstract

Analysis of longitudinally obtained HIV-1 env sequences from an individual with reported cross-reactive neutralizing activity revealed that the majority of viral variants obtained from serum between 4 and 7 years after seroconversion were unable to persist in peripheral blood. Here we show that these viral variants were more sensitive to autologous serum neutralization, had shorter envelopes with fewer potential N-linked glycosylation sites, and showed lower replication kinetics than successfully evolving HIV-1 variants. These data reflect the host selection pressures on phenotypic characteristics of HIV-1 and illustrate in detail the dynamic interaction between HIV-1 and its host's humoral immune responses.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21653664      PMCID： PMC3147988          DOI： 10.1128/JVI.05214-11

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  36 in total

1.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?

Authors:  Dan H Barouch; Norman L Letvin
Journal:  Lancet       Date:  2004 Jul 3-9       Impact factor: 79.321

3.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

4.  Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection.

Authors:  David Kwa; Jose Vingerhoed; Brigitte Boeser; Hanneke Schuitemaker
Journal:  J Infect Dis       Date:  2003-04-09       Impact factor: 5.226

5.  Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1.

Authors:  R P van Rij; H Blaak; J A Visser; M Brouwer; R Rientsma; S Broersen; A M de Roda Husman; H Schuitemaker
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

8.  Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection.

Authors:  Fransje A Koning; David Kwa; Brigitte Boeser-Nunnink; Jos Dekker; Jose Vingerhoed; Harry Hiemstra; Hanneke Schuitemaker
Journal:  J Infect Dis       Date:  2003-09-04       Impact factor: 5.226

Review 9.  Diversity considerations in HIV-1 vaccine selection.

Authors:  Brian Gaschen; Jesse Taylor; Karina Yusim; Brian Foley; Feng Gao; Dorothy Lang; Vladimir Novitsky; Barton Haynes; Beatrice H Hahn; Tanmoy Bhattacharya; Bette Korber
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

10.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823
View more
  4 in total

1.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

Review 2.  Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection.

Authors:  Michelle D Tate; Emma R Job; Yi-Mo Deng; Vithiagaran Gunalan; Sebastian Maurer-Stroh; Patrick C Reading
Journal:  Viruses       Date:  2014-03-14       Impact factor: 5.048

3.  Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.

Authors:  Heidi E Drummer; Melissa K Hill; Anne L Maerz; Stephanie Wood; Paul A Ramsland; Johnson Mak; Pantelis Poumbourios
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

4.  Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.

Authors:  Antoine Chaillon; Martine Braibant; Stéphane Hué; Samia Bencharif; David Enard; Alain Moreau; Assia Samri; Henri Agut; Francis Barin
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.